[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BioCentury posts on X about kong, hong kong, $216m, $439m the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence finance XXXX% stocks XXXX% travel destinations XXXX%
Social topic influence kong 3.03%, hong kong 3.03%, $216m 1.52%, $439m 1.52%, finance 1.52%, $192m 1.52%, asia 1.52%, novartis 1.52%, money 1.52%, $1530hk XXXX%
Top accounts mentioned or mentioned by @jeff_cranmer @marketwirenews @usfdas @usfda @cincorpharma @albireopharma @biocenturys @wuxiapptec @wuxibiologics @seemacms @scottgottliebmd @nea @davidthomascfa @fishburnsimone @nociftw @biopharmajosh @cbtadvisors @flyingeagle86 @lcccc333
Top assets mentioned Novartis AG (NVS)
Top posts by engagements in the last XX hours
"Rare disease setbacks for Ultragenyx mid-stage win for Rhythm. Plus: Astrazeneca and Takeda preparing submissions after Phase III readouts in this weeks Clinical Report" @BioCentury on X 2025-07-15 22:30:12 UTC 16.3K followers, XXX engagements
"In BioCentury's Venture Report: Australia's Brandon Capital closed its sixth fund at A$439M far outsizing the firm's previous vehicles; plus Dispatch's $216M launch and more" @BioCentury on X 2025-07-24 23:00:07 UTC 16.3K followers, XXX engagements
"Capital flows continue in Asia. Ascentage Pharma raises $192M in Hong Kong placement while Korea-based Illimis raises $XX million in a series B round: BioCentury's latest Finance Report" @BioCentury on X 2025-07-18 21:30:12 UTC 16.3K followers, XXX engagements
"Third patient dies from acute liver failure caused by a Sarepta gene therapy" @BioCentury on X 2025-07-18 00:00:08 UTC 16.3K followers, 93.2K engagements
"BioCentury's latest biopharma Management Moves: Steve Bates longtime head of BIA named executive chair of U.K.s Office of Life Sciences. Plus: Novartis names Mazuk chief patient experience officer and updates from Seres and ABPI" @BioCentury on X 2025-07-22 22:30:04 UTC 16.3K followers, XXX engagements
"Seed/Series A money up in 1H25 but mostly a few companies raising monster rounds: a BioCentury Data Byte" @BioCentury on X 2025-07-18 19:30:10 UTC 16.3K followers, XXX engagements
"In BioCentury's Public Equity Report: Amid a difficult stretch for IPOs Nanjing Leads Biolabs has priced a HK$1.5B offering in Hong Kong; plus Abivax's $747.5M follow-on Pfizer's investment in 3SBio and more" @BioCentury on X 2025-07-25 20:30:12 UTC 16.3K followers, XXX engagements